CANCER survivors: A 30-minute routine slashes recurrence risk
In January of 2025, there were more than 18 million folks in the U.S. living with a history of cancer. That includes 4.3 million folks who have battled breast cancer and 3.5 million who have survived prostate cancer. About half were diagnosed in the past 10 years and nearly 80% are 60 or older. That's a lot of folks who are breathing a sigh of relief -- and hoping that their cancer never returns or metastasizes.
Well, there's some very good news. A preliminary study published in Breast CANCER Research and Treatment reveals that a 30-minute bout of either resistance or high-intensity interval training boosts levels of anti-cancer myokines -- they're proteins produced by muscles which have anti-cancer effects and could reduce the proliferation of cancer growth by 20% to 30%!
When you add the power of exercise to improve lean muscle mass and reduce fat mass, so you also quell inflammation, you're revving up even more protection from recurring cancer.
The researchers also stress that whether you are undergoing cancer treatment, have just finished your treatment regimen or are a cancer survivor, you can benefit from working with your doctor to develop a five-day-a-week exercise routine that's right for you. (As you become stronger and more able to exercise, upgrade and expand what you do.)
For more information on how to tamp down chronic inflammation and reduce your risk of cancer or its recurrence, check out the revised edition of "YOU: The Owner's Manual" and sign up for the free newsletter at 4YOUngevity.com.
Health pioneer Michael Roizen, M.D., is chief wellness officer emeritus at the Cleveland Clinic and author of four No. 1 New York Times bestsellers. Check out his latest, "The Great Age Reboot: Cracking the Longevity Code for a Younger Tomorrow," and find out more at www.longevityplaybook.com. Email your health and wellness questions to Dr. Mike at questions@longevityplaybook.com.
(c)2023 Michael Roizen, M.D.
Distributed by King Features Syndicate, Inc.
(c) 2025 Michael Roizen, M.D. Distributed by King Features Syndicate, Inc.
Comments